DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-cell lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-cell lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report

• DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Diffuse Large B-Cell Lymphoma treatment.
• The leading companies working in the Diffuse Large B-Cell Lymphoma Market include Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, Pharmacyclics LLC., Shanghai Yingli Pharmaceutical, Philogen, Amgen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., JW Therapeutics, Incyte Corporation, BeiGene, Miltenyi Biotec GmbH, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb, Celleron Therapeutics, Otsuka Pharmaceutical, Curis Inc., Bayer, Kartos Therapeutics Inc., Shanghai Institute Of Biological Products, Novartis Pharmaceuticals, Constellation Pharmaceuticals, Secura Bio Inc., CytomX Therapeutics, Juno Therapeutics, Teneobio Inc., Telios Pharma, Inc., Sorrento Therapeutics Inc., Curocell Inc., TG Therapeutics Inc., Tessa Therapeutics, TCR2 Therapeutics, Plexxikon, Shattuck Labs Inc., MEI Pharma Inc., Boryung Pharmaceutical Co., Ltd, Sutro Biopharma Inc., Newave Pharmaceutical Inc., Eden BioCell Ltd., Adicet Bio Inc., VelosBio Inc., Seagen Inc., Eisai Co Ltd, Nurix Therapeutics Inc., Prelude Therapeutics, Xencor, and others.
• Promising Diffuse Large B-Cell Lymphoma Pipeline Therapies in the various stages of development include Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, Maplirpacept (PF-07901801), Glofitamab, Obinutuzumab, GNC-038, Tafasitamab, Bendamustine (BEN), and others.
• December 2023: Regeneron Pharmaceuticals announced a study of Phase 3 clinical trials for Odronextamab, Rituximab, Cyclophosphamide and Doxorubicin. This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (called “previously untreated”), have come back after treatment (called “relapsed”), or have not responded to treatment (called “refractory”).
• December 2023: Merck Sharp & Dohme LLC announced a study of Phase 2 clinical trials for MK-2140 (zilovertamab vedotin). The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, and interventional study.

 

Request a sample and discover the recent advances in Diffuse Large B-Cell Lymphoma Treatment Drugs @ Diffuse Large B-Cell Lymphoma Pipeline Outlook Report

 

In the Diffuse Large B-Cell Lymphoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Diffuse Large B-Cell Lymphoma NDA approvals (if any), and product development activities comprising the technology, Diffuse Large B-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Diffuse Large B-Cell Lymphoma Overview

Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections.

 

Find out more about Diffuse Large B-Cell Lymphoma Therapeutics Assessment @ Diffuse Large B-Cell Lymphoma Preclinical and Discovery Stage Products

 

Diffuse Large B-Cell Lymphoma Emerging Drugs Profile

• Epcoritamab: Genmab
• Glofitamab: Roche
• Acalabrutinib: Acerta Pharma
• AUTO 3: Autolus
• Abexinostat: Xynomic Pharmaceuticals

 

Diffuse Large B-Cell Lymphoma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the Diffuse Large B-Cell Lymphoma therapies. The Diffuse Large B-Cell Lymphoma companies which have their Diffuse Large B-Cell Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genmab.

 

DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

 

Learn more about the emerging Diffuse Large B-Cell Lymphoma Pipeline Therapies @ Diffuse Large B-Cell Lymphoma Clinical Trials Assessment

 

Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report

• Coverage- Global
• Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Diffuse Large B-Cell Lymphoma Companies– Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, Pharmacyclics LLC., Shanghai Yingli Pharmaceutical, Philogen, Amgen, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., JW Therapeutics, Incyte Corporation, BeiGene, Miltenyi Biotec GmbH, Beijing InnoCare Pharma Tech Co., Ltd., Bristol-Myers Squibb, Celleron Therapeutics, Otsuka Pharmaceutical, Curis Inc., Bayer, Kartos Therapeutics Inc., Shanghai Institute Of Biological Products, Novartis Pharmaceuticals, Constellation Pharmaceuticals, Secura Bio Inc., CytomX Therapeutics, Juno Therapeutics, Teneobio Inc., Telios Pharma, Inc., Sorrento Therapeutics Inc., Curocell Inc., TG Therapeutics Inc., Tessa Therapeutics, TCR2 Therapeutics, Plexxikon, Shattuck Labs Inc., MEI Pharma Inc., Boryung Pharmaceutical Co., Ltd, Sutro Biopharma Inc., Newave Pharmaceutical Inc., Eden BioCell Ltd., Adicet Bio Inc., VelosBio Inc., Seagen Inc., Eisai Co Ltd, Nurix Therapeutics Inc., Prelude Therapeutics, Xencor, and others.
• Diffuse Large B-Cell Lymphoma Pipeline Therapies– Epcoritamab, Cyclophosphamide, Rituximab, Lenalidomide, Maplirpacept (PF-07901801), Glofitamab, Obinutuzumab, GNC-038, Tafasitamab, Bendamustine (BEN), and others

 

Dive deep into rich insights for new drugs for Diffuse Large B-Cell Lymphoma Treatment, Visit @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Diffuse Large B-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diffuse Large B-Cell Lymphoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Diffuse Large B-Cell Lymphoma Collaboration Deals
9. Late Stage Products (Phase III)
10. Epcoritamab: Genmab
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Abexinostat: Xynomic Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I/II)
16. AUTO 3: Autolus
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Diffuse Large B-Cell Lymphoma Key Companies
20. Diffuse Large B-Cell Lymphoma Key Products
21. Diffuse Large B-Cell Lymphoma- Unmet Needs
22. Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
23. Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
24. Diffuse Large B-Cell Lymphoma Analyst Views
25. Diffuse Large B-Cell Lymphoma Key Companies
26. Appendix

 

For further information on the Diffuse Large B-Cell Lymphoma Pipeline therapeutics, reach out to Diffuse Large B-Cell Lymphoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market